Patents by Inventor Kamsa Pae

Kamsa Pae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
    Patent number: 9464044
    Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: October 11, 2016
    Assignees: AHN-GOOK PHARMACEUTICAL CO., LTD., BAMICHEM CO., LTD, INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Soon Kil Ahn, Jin Auh, Nam Song Choi, Chang Kyun Han, Tae-Jeong Kim, Kamsa Pae, Young June Shin, Dong-Oh Han, Cheol Kyu Han
  • NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
    Publication number: 20150210635
    Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.
    Type: Application
    Filed: June 4, 2013
    Publication date: July 30, 2015
    Inventors: Soon Kil Ahn, Jin Auh, Nam Song Choi, Chang Kyun Han, Tae-Jeong Kim, Kamsa Pae, Young June Shin, Dong-Oh Han, Cheol Kyu Han